The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Lintuzumab-Ac225 in combination with CLAG-M following venetoclax+HMA in TP53-mutated R/R AML
Guru Subramanian Guru Murthy, MD, Medical College of Wisconsin, Milwaukee, WI, shares insights into a Phase I clinical trial (NCT03441048) evaluating lintuzumab-Ac225 in combination with CLAG-M in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). Dr Guru Murthy reports new data on the outcomes of a subpopulation of patients who received prior therapy with hypomethylating agents (HMAs) in combination with venetoclax, focusing on those with TP53-mutated disease. The regimen was effective, with a composite complete response (CR) rate of 38.5% and an overall response rate (ORR) of approximately 53.8%. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
